Advisor Group Holdings, Inc. X4 Pharmaceuticals, Inc Transaction History

Advisor Group Holdings, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.58 - $1.47 $231 - $588	400 New	400 $0
Q1 2023 May 12, 2023	SELL	$0.8 - $1.22 $3,552 - $5,416	-4,440 Reduced 89.35%	529 $0
Q2 2022 Aug 10, 2022	BUY	$0.88 - $1.91 $3,581 - $7,773	4,070 Added 452.73%	4,969 $5,000
Q1 2022 May 04, 2022	BUY	$1.48 - $2.58 $738 - $1,287	499 Added 124.75%	899 $117,000
Q1 2021 May 13, 2021	BUY	$6.63 - $10.28 $2,652 - $4,112	400 New	400 $3,000

99.6M

421K

80.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $17.2M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.